HIV-associated neurocognitive disorder (HAND) often complicates HIV infection despite combination antiretroviral therapy (ART) and may be influenced by host genomics. We performed a genome-wide association study (GWAS) of HAND in 1,050 CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Study participants. All participants underwent standardized, comprehensive neurocognitive, and neuromedical assessments to determine if they had cognitive impairment as assessed by the Global Deficit Score (GDS), and individuals with comorbidities that could confound diagnosis of HAND were excluded. Neurocognitive outcomes included GDS-defined neurocognitive impairment (NCI; binary GDS, 366 cases with GDS ! 0.5 and 684 controls with GDS < 0.5, and GDS as a continuous variable) and Frascati HAND definitions that incorporate assessment of functional impairment by self-report and performance-based criteria. Genotype data were obtained using the Affymetrix Human SNP Array 6.0 platform. Multivariable logistic or linear regressionbased association tests were performed for GDS-defined NCI and HAND. GWAS results did not reveal SNPs meeting the genomewide significance threshold (5.0 Â 10
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INTRODUCTION
HIV-associated neurocognitive disorder (HAND) remains a common complication of HIV infection in the combination antiretroviral therapy (ART) era. Although modern ART has substantially improved life expectancy and reduced the incidence of HIVassociated dementia (HAD), milder forms of HAND remain prevalent, including asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND). The overall prevalence of HAND is 30-50% among unselected HIV-infected persons [Grant, 2008; Heaton et al., 2010] and is predominantly driven by the ANI category, which predicts decline to symptomatic neurocognitive impairment (NCI) . The neuropathogenesis of HIV-infection remains incompletely understood, although potential risk factors include persistent low-level central nervous system (CNS) HIV infection, chronic immune activation, and accelerated aging, among others [Heaton et al., 2011; Fogel et al., 2015; Horvath and Levine, 2015] .
Host genetics plays a significant role in many neuropsychiatric disorders and has been studied with increasing interest for its potential contribution to HIV disease complications, including HAND [Kallianpur and Levine, 2014] . Variants in genes regulating multiple biological processes may impact the risk of NCI, progression of HAND, and response to ART. Candidate-gene association studies [Burt et al., 2008; Bol et al., 2012] and a single published genome-wide association study (GWAS) [Levine et al., 2012] revealed promising genetic variants associated with HAND, including variants in immune-related genes [Pemberton et al., 2008] , ion channel transporters , and genes related to nuclear and mitochondrial DNA damage [Kallianpur and Levine, 2014] . However, most of these associations failed to reach genome-wide statistical significance and have either not been subjected to independent replication attempts, or have not been successfully replicated in subsequent studies, due at least in part to phenotypic and population differences between studies. To be successful, GWAS ideally requires large sample sizes, meticulous and standardized phenotyping, and careful attention to population stratification, and few studies combining neurocognitive and genome-wide genetic data across cohorts for GWAS or meta-analyses have been undertaken to date. In the single published GWAS that was conducted specifically to evaluate HAND [Levine et al., 2012] , no prior single-nucleotide polymorphism (SNP) association was replicated, and no new SNP association reached genome-wide statistical significance (P ¼ 5 Â 10 À8 ). In this study, we conducted a GWAS of HAND in participants in the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Study [Heaton et al., 2010] , which was specifically designed to study neurological outcomes in HIV infection and is the largest U.S.-based prospective study of neurological complications of HIV/AIDS in the ART era. We performed genome-wide genotyping and comprehensive quality control (QC), resulting in a working dataset comprising 1,050 individuals. For phenotype definition, we employed a commonly used and validated measure of NCI, the global deficit score (GDS). We conducted genome-wide association tests using the GDS score as a dichotomous or continuous variable and Frascati criteria for HAND to define clinical phenotypes. Although we did not discover SNPs meeting the genome-wide (Bonferroni) criterion for statistical significance, we did identify new and promising genes with biological plausibility, and P values approaching this threshold, which warrant further investigation.
METHODS

Study Population
DNA samples were collected from 1,082 CHARTER study participants. CHARTER is a prospective, observational study of neurobehavioral outcomes of HIV disease, which enrolled ambulatory, HIV-infected adults from 2003 to 2007 at six U.S. medical centers. Study participants underwent detailed, structured interviews, and laboratory assessments to obtain information on HIV disease and treatment-related factors, including nadir CD4þ T-cell counts, ART history, nucleoside reversetranscriptase inhibitor (NRTI) exposure, history of a major depressive disorder, substance use/dependency, comorbidity, and demographics. Data were also collected on current CD4þ T-cell count, HIV RNA levels in plasma, and hepatitis C virus serology. Details regarding CHARTER study eligibility criteria, enrollment, and follow-up procedures have been published previously [Heaton et al., 2011 . CHARTER is approved by the Institutional Review Boards of all participating sites and abides by the Declaration of Helsinki; all study participants provided written informed consent. Comorbid conditions of participants were determined by experienced clinicians to be either minimal ("incidental" to NCI), or mild to moderate severity ("contributing" to NCI) [Heaton et al., 2010] . To minimize confounding by conditions other than HIV infection, individuals with severe comorbid conditions that would make it impossible to attribute NCI to HIV infection (e.g., individuals with a history of traumatic brain injury with prolonged loss of consciousness, or developmental learning disorders) were excluded from genetic analyses. Detailed descriptions of minimal, mild/moderate comorbidities, their determinations, and frequency in CHARTER have been presented elsewhere [Antinori et al., 2007; Heaton et al., 2010; Kallianpur et al., 2016] .
Neurocognitive Phenotypes
All participants were assigned a GDS value at their first or baseline visit [Kallianpur et al., 2016] . GDS was analyzed as a continuous measure in HIV-infected persons. Following a conventional threshold [Blackstone et al., 2012] , we categorized participants as cases and controls according to their GDS values at baseline, that is, cases with GDS-defined NCI were individuals with GDS ! 0.5, while controls were those with GDS < 0.5. The binary GDS cutoff of 0.5 is standard in studies of neurocognition in CHARTER and has also been used in other HIV-related studies of neurocognitive function that employ the same test battery [Blackstone et al., 2012] . We assigned two GDS-related phenotypes: one quantitative, using continuous GDS values and the other categorical, termed "binary GDS."
We also explored different clinical subcategories of HAND using the well-accepted Frascati criteria [Antinori et al., 2007] which incorporate information from self-report regarding functional status. All CHARTER participants were classified into four subgroups, either one of three impaired subgroups (n ANI ¼ 359, n MND ¼ 92, and n HAD ¼ 30), or neuropsychiatrically normal (n NCN ¼ 568). One individual with a GDS value lacked a HAND assessment. For the purpose of GWAS analyses, we compared different categories of HAND according to the severity of functional impairment and also combined specific groups for comparison, including "all HAND" versus No HAND (NCN), (ANI and MND) versus NCN, MND versus NCN, and ANI versus NCN. The GDS is more conservative for establishing presence of NCI than the Frascati criteria, but a GDS > 0.5 virtually guarantees that Frascati criteria are also met [Blackstone et al., 2012] . The GDS as a continuous variable provides additional information regarding the severity of NCI. Therefore, we used GDS for the cognitive impairment definition and HAND categories (Frascati criteria) for establishing symptomatic status and ruling out confounds. To focus the presentation of results, we present the results of GWAS analyses of HAND phenotypes in the Supplementary Results.
Genotyping
Genomic DNA was extracted from peripheral blood mononuclear cells collected at the baseline CHARTER visit using PUREGENE (Gentra Systems, Inc., Minneapolis, MN). All samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 TM . Genotyping was conducted by the Vanderbilt Technologies for Advanced Genomics (VANTAGE) at Vanderbilt University in two batches: 576 samples were genotyped before 2009 and 506 (six were repeats for QC) were genotyped in 2012. Notably, all CHARTER study participants were recruited prior to 2009; however, genotyping was performed in two batches due only to funding availability, rather than to technical, or biological concerns. We applied the same QC procedure and analysis pipeline, however, for all samples combined. Nevertheless, batch effect was tested explicitly, and only minor changes were observed (see Results).
Quality Control (QC)
We first checked the call rate per individual, which was found to be >95% in all samples. A sex check was performed using PLINK to compute the homozygosity rate of X-chromosome (the F value). F value is close to 1 for male and is less than 0.2 for female; hence, it can be used to predict sex information. Individuals with discrepant sex information were categorized as female or male based on their F values. Samples with misclassified or discrepant sex information were reviewed, double-checked, and revised as necessary. There were 21 samples that were self-reported as female but had an F-value between 0.2 and 0.5. These individuals were assigned as female. Samples with extreme missing rates or heterozygosity rates were also detected using PLINK and removed following the protocol in [Anderson et al., 2010] . Unknown relatedness and duplicated individuals were assessed using pairwise identity-by-state (IBS) and identity-by-descent (IBD) estimations. The parameter PI_Hat, which was computed by PLINK for any pair of samples, was used to determine sample correlations. For pairs with high PI_Hat values (i.e., >0.2), the sample with a higher missing rate was removed from the analysis. In total, 28 samples were removed, including technical repeats and controls.
Our samples included self-reported European American (EA), African American (AA), Hispanic (H), and others. We merged CHARTER samples with HapMap samples from four populations. We then performed Principal Component (PC) Analysis using EIGENSOFT [Patterson et al., 2006 ] to assess population stratification. To avoid high linkage disequilibrium (LD) between SNPs, we used the r 2 parameter, with r 2 threshold set to 0.5. This PC analysis process identified two individuals who had greater than six standard deviations (SDs) from the mean for five iterations (default). These two individuals were removed. The PC analysis also identified two samples whose self-reported ethnicity was inconsistent with what the PCs suggested. One sample was self-reported as AA and the other was self-reported as Hispanic but both were predicted to be EA according to the first and second PCs. However, because our association test did not distinguish between these subpopulations, we included the two samples with inconsistent race/ethnicity in the analysis.
Finally, SNPs that failed the Hardy-Weinberg exact test were removed (P < 10 À6 ). After removing problematic samples, we obtained a cleaned dataset with high-quality SNPs. We then performed PC analysis again using the cleaned dataset and SNPs (minor allele frequency or MAF > 0.05) to generate PC covariates.
Association Analyses
For dichotomous phenotypes, we used logistic regression, and for continuous phenotypes, linear regression was applied. For all HAND and NCI phenotypes, we adjusted for the following parameters as covariates: age (continuous variable), nadir CD4þ Tcell count (cells/ml, abbreviated as "nadir CD4," continuous variable), plasma viral load ("plasma VL," continuous variable), ART use (categorical variable with two levels: current use or non-use), Wide-Range Achievement Test (WRAT) [Casaletto et al., 2014; Heaton et al., 2015; Olsen et al., 2015] (continuous variable), comorbidity status (binary variable: contributing or incidental to NCI), and the first and second PCs, PC1, and PC2. These covariates were selected based on expert review or statistically significant differences in univariate analyses; they were also found to reduce the inflation of test statistics. For the additive effects of SNPs, we report the regression coefficient (b, linear regression) and the odds ratio (OR, logistic regression), which represent the effect of the minor allele denoted by A1 (i.e., a positive regression coefficient indicates that the minor allele increases the risk of NCI) [Purcell et al., 2007] . All analyses were conducted using PLINK. Manhattan plots and Quantile-Quantile (QQ) plots were generated using R. Plots of representative SNPs were generated using LocusZoom software.
RESULTS
Sample Characteristics and Genotyping QC
The cleaned dataset included 1,050 individuals (811 male and 239 female) with high-quality genotype data and phenotype information. CHARTER study participants are racially and ethnically diverse. Combined analysis of CHARTER samples and the reference HapMap samples showed that self-reported race information was highly consistent with ancestry predicted by genotype data, with a few outliers ( Figs. 1 and 2 ). Categorized as "minimal" or "not contributing" to NCI versus "contributing" to NCI.
A detailed description of baseline participant characteristics is presented in Table I . A quantitative phenotype was defined using GDS as a continuous variable, ranging between 0 and 4.17 in this sample (mean ¼ 0.46). Individuals were categorized as cases or controls using a GDS threshold of 0.5 (n ¼ 366 with GDS ! 0.5, referred to as the group with GDS-defined impairment, or imp) and controls (n ¼ 684 with GDS < 0.5, referred to as unimp) according to the GDS (Table I ). The overall distribution of GDS was presented in Supplemental Figure S1 . GDS phenotypes were not significantly associated with age (P ¼ 0.72 for continuous GDS and P ¼ 0.64 for binary GDS, Table II) . GDS values differed among different ethnicity groups (Fig. 3) and were notably higher (worse) among Hispanic participants than in other ethnic groups and lower (better) among self-reported (non-Hispanic) black individuals than in other population subgroups, a finding consistent with prior CHARTER analyses .
A related categorical definition of HAND was also evaluated, based on self-report of functional status and published Frascati criteria [Antinori et al., 2007] . Comparisons of the GDS between HAND subcategories are shown in Figure 1 . Individuals with HAD, as anticipated, had significantly higher GDS than individuals with other forms of HAND.
Covariate Effects
We performed linear or logistic regression analysis of each covariate with each phenotype to determine the effect of covariates. Statistical results are presented in Table II (GDS-related phenotypes) and in Supplemental Table SI (HAND-related phenotypes). According to these results, nadir CD4, plasma VL, WRAT score, comorbidity status (contributing vs. incidental to NCI), and PC1 were significantly (P < 0.05), or marginally (P < 0.1), associated with either or both GDS phenotypes, supporting the selection of these covariates Kallianpur et al., 2016] for inclusion in subsequent multivariable analyses of genotype associations with GDSdefined NCI or HAND. 
Association Results
By fitting linear regression models (for continuous GDS) or logistic regression models (for binary GDS), we conducted association tests for all evaluable SNPs genome-wide. We calculated the genomic inflation factor for each result, which was found to range between 0.99 and 1.02 for all phenotypes, indicating that our QC process was highly effective, with well-controlled genomic inflation. Visualization of the QQ plots of P values also showed that the majority of SNPs had expected P values following approximately the line y ¼ x, and the most significant SNPs departed from the expectation dramatically (Fig. 4 and Supplemental Fig. S2) .
Notably, we examined additional PCs (i.e., PC3 and PC4) for their potential association with these phenotypes. We compared P values obtained by including either two PCs plus other biological covariates in regression models, or four PCs plus other covariates. As shown in Supplemental Figure S3 , we observed highly consistent results. Thus, we determined that the third and fourth PCs had minor impact on our results. In addition, neither PC3 nor PC4 was significantly associated with GDS phenotypes. Taken together, the inclusion of PC1 and PC2 was sufficient to control for population stratification in multivariable analyses.
No SNP met the genome-wide significance (5 Â 10 À8 ) criterion for association with either GDS-related phenotype ( Fig. 5 and Table III) , or with any of the four Frascati-defined HAND phenotypes (Supplemental Fig. S4 ). We list the top 10 most significant SNPs for each phenotype in Table IV and Supplemental Tables SII-SV . For continuous GDS, the most significant SNP was rs11157436 (P ¼ 1.26 Â 10 À7 ) located on chromosome 14 and in the gene region of T-cell receptor alpha locus (TRAa). Three other SNPs, located nearby, were also found among the top 10 most significant genes: rs12437004 (P ¼ 4.41 Â 10 À7 ), rs1076546 (P ¼ 7.31 Â 10 À7 ), and rs2293731 (P ¼ 2.88 Â 10 À6 ). All four SNPs were highly correlated with one another and in LD (Fig. 6) . The second most significant SNP associated with continuous GDS was located on chromosome 19, rs12460243 (P ¼ 3.73 Â 10 À7 ), which was located in the intergenic region between the genes CCL25 and FBN3. For binary GDS, the most significant SNPs were rs6542826 (P ¼ 8.06 Â 10 À7 ) and rs11681615 (1.22 Â 10 À6 ) located on chromosome 2 and in the gene SH3RF3. The next most significant SNP was located on chromosome 3, rs9814567 (P ¼ 1.38 Â 10 À6 ), located in the gene CEP63.
Considering that our study sample comprises at least three populations (EA, AA, and, Hispanic), we also reported allele frequencies for the top SNPs in each population (Table IV) .
We also tested the effect of batch by including it as a covariate. As shown in Supplemental Table SVI, the P values obtained with or without the batch effect showed minor changes. The top SNPs remained nearly the same with or without inclusion of batch in the models.
Examination of SNPs Implicated in Previous Studies
Iron-related genes have been previously implicated in neurological complications of HIV infection in our studies . We also evaluated 20 iron-related candidate genes noted to be of interest previously as part of a nested candidate-gene analysis, based on their direct or indirect roles in iron metabolism, transport, storage, and/or
FIG. 4. Q-Q plot of the genome-wide association study (GWAS) results for GDS as a binary phenotype (left) or GDS as a quantitative phenotype (right). The gray area indicates 95% confidence interval (CI). [Color figure can be viewed at wileyonlinelibrary.com]
regulation, and on the existence of prevalent SNPs in these genes. We examined the association of these iron-metabolismrelated SNPs with GDS (Table V) . A total of 391 SNPs located within or around (20 kb upstream or downstream) these iron-related genes were genotyped in our dataset. The most significant SNP in these genes associated with GDS as a quantitative phenotype was rs7753111 (P ¼ 1.91 Â 10 À3 ) in BMP6, and another SNP associated with binary GDS was rs1690313 (P ¼ 3.73 Â 10 À3 ) in B2M. In our prior study , both genes were found to harbor SNPs that were associated with neuropathic pain, but the SNPs identified were not identical to those observed here.
We also evaluated 19 SNPs that were implicated in previous GWAS or association studies of HAND, including rs1130371 (MIP1-a), rs1800629 (TNF-a), rs1024611 (MCP-1), rs1801157 (CXCL12), rs2839619 (PKNOX1), rs1800450 (MBL2), rs1800451 (MBL2), and rs5030737 (MBL2) [Levine et al., 2012] . Only five SNPs were represented in our data, and only one SNP, rs1024611 in the gene MCP1 (monocyte chemoattractant protein-1), was found to be nominally significant in association with binary GDS (P ¼ 0.023) ( Table VI) . In CHARTER, APOE-e4 genotype has not been associated with HAND or with HIV neuroimaging outcomes in older HIV-infected persons [Morgan et al., 2013; Cooley et al., 2016] , and it did not emerge in this GWAS.
Comparison of Significant SNPs Across Phenotypes
We compared the top SNPs associated with GDS as a continuous variable and as a categorical variable (Fig. 7) . We evaluated the top SNPs with P < 10 À3 , P < 10 À4 , and P < 10 À5 . Although binary and continuous GDS phenotypes are expected to be correlated, we observed relatively few SNPs common to both phenotypes at each P-value cut-off. A single SNP, rs4772857 in gene FAM155A, overlapped all of these phenotypes at P < 10 À5 (Fig. 7) . Eight SNPs were associated with both binary GDS and continuous GDS at P < 10 À4 , and 112 SNPs overlapped these phenotypes at P < 10 À3 (13% of continuous GDS SNPs and 15% of binary GDS SNPs). We found no overlapping SNPs among the 10 most significant SNPs identified for each phenotype (see above, Table IV ). While both GDS outcomes represent related measures, binary GDS may be a more clinically relevant measure of NCI, while GDS as a continuous measure may be more powerful for detecting genetic effects among those participants who are only mildly impaired.
Additionally, we compared the top SNPs among all six phenotypes. We defined the top SNPs with different cutoff values as P < 10 À3 , P < 10 À4 , P < 10 À5 , and P < 10 À6 (Supplemental Fig. S5 ).
DISCUSSION
We conducted a GWAS among CHARTER study participants with or without cognitive impairment phenotypes, defined by either the GDS or Frascati (HAND) criteria at enrollment. While no SNPs meeting stringent, genome-wide (Bonferroni) significance criteria were associated with any of the neurocognitive phenotypes, several biologically plausible associations approaching the GWAS level of significance were identified in multivariable analyses, adjusting for numerous host-and HIV-related potential confounders. Our results therefore, provide candidate SNPs and variants for future validation. Several associations with biological potential include four SNPs (rs11157436, rs12437004, rs1076546, and rs2293731) in the T-cell receptor-alpha (TCRa) locus, two SNPs in FBN3 and CCL25 (rs12460243 and rs17154702), and two SNPs in the gene SH3RF3. Studies in knock-out mouse models have established that the gene TCRa has an important role in adult neurogenesis [Huang et al., 2010] , particularly in the hippocampus, an area of the brain involved in the HAND phenotype. The SH3RF3 gene (and the SH3 domain) has been associated with age of onset in familial Alzheimer's disease [Lee et al., 2015] . At a Type I error cut-off of P < 10 À4 , eight SNPs were associated with both binary GDS and continuous GDS. Several intronic variants, as well as SNPs in CNTN6, RAP1GAP, FAM155A, KY, PXDNL, and CSMD1, were also among the top SNPs identified. Interestingly, ANAPC13, CEP63, and KY were also among genes whose predicted RNA expression values based on genomic sequence were associated with GDS in CHARTER (P ¼ 3 Â 10 À7 and 1 Â 10 À6 , respectively, Kallianpur, Hulgan, and Bush et al., unpublished data) . ANAPC13 functions in the ubiquitin-mediated proteolysis pathway. CNTN6 encodes a neural adhesion molecule which has been associated with intellectual disability [Kashevarova et al., 2014] in children, and copy number variants in this gene have recently been identified it as a candidate for a wide spectrum of neurobehavioral disorders [Hu et al., 2015] ; this gene may also function in a large number of protein interaction networks important for normal brain development [Zuko et al., 2016] . The gene CSMD1 has been associated with sporadic Alzheimer's disease [Parcerisas et al., 2014] , schizophrenia [Koiliari et al., 2014] , cannabis dependence [Koiliari et al., 2014] , and other neuropsychiatric disorders. FBN3 encodes an extracellular matrix molecule, which has been shown to be regulated by iron in animal studies [Hill et al., 2007] . Fibrillins have emerged as critical mediators of the immune response and, like other extracellular matrix proteins, may have a particular role in regulating neuroinflammation [Summers et al., 2013; Zeyer and Reinhardt, 2015] . The chemokine CCL25 is important for T-cell homing and antigen-specific mucosal immunity, both of which are defective in HIV and simian immunodeficiency virus (SIV) infection [Qin et al., 2008; Mavigner et al., 2012] . Microbial translocation across the gut mucosa is postulated to contribute to HIV-associated persistent immune activation and neurocognitive dysfunction [Hoenigl et al., 2016] .
A number of iron-regulatory gene variants, many of which were within the same gene or genes known to be closely related (HEPH and CP) were also nominally associated with binary GDS or continuous GDS outcomes, three of which were shared between these phenotypes (B2M, BMP6, and HEPH). Genes CP, SLC40A1, FTH1, and SLC11A2 were also nominally associated with GDS-defined HAND in this study and have been associated (after adjustment for multiple testing) with HAND-related neuroimaging traits in CHARTER (e.g., subcortical gray matter volume, abnormal white matter volume, and basal ganglia choline (unpublished data [Thornton-Wells et al., 2015] ). HEPH encodes the membrane-based homolog of ceruloplasmin (encoded by CP). The gene FTH1 has been associated with HIVmediated dysregulation of CXCL12/CXCR4 signaling in HIVpositive persons with a history of opioid abuse [Bandaru et al., 2011] . Finally, SNP rs1024611 in MCP1, which is one of very few genes that have been replicated in previous candidate-gene association studies of HAND, was also associated with HAND at a nominal level of significance in our study. MCP-1 is an important chemokine with postulated roles in immune activation and monocyte-mediated neuro-inflammation in HIV infection [Kelder et al., 1998; Bethel-Brown et al., 2012; Marcotte et al., 2013] . In this CHARTER study, the MCP-1 G allele was linked nominally to reduced risk of HAND, whereas prior studies have suggested increased or no change in risk [Bol et al., 2012; Levine et al., 2012] . Prior associations of rs1024611 in the MCP1 gene (G allele) with HAND have been similarly inconsistent, possibly due to interacting polymorphisms in the PREP1 gene or significant differences in population stratification [Kallianpur and Levine, 2014] . Notably, the SNPs in iron-related genes were only nominally significant, and these associations would not survive multipletesting correction. Caution is therefore needed when interpreting these results. Future studies with a significantly larger sample size are necessary to potentially validate these results. Only one prior GWAS of HAND has been published to date (see [Levine et al., 2012] ). In that study of 1,287 HIV-infected men from the Multicenter AIDS Cohort Study (MACS), no novel genetic susceptibility loci were found to be associated at genomewide levels of significance with HAD, neurocognitive decline over time, or either information processing speed or executive function domains, based on a combination of structured clinical interviews and neuropsychological tests. That study combined three different clinical datasets, and several genotyping platforms were used to generate genomic data, introducing additional heterogeneity into analyses. Particular strengths of the present CHARTER analysis include the racial/ethnic diversity of the population we studied (N ¼ 1,050, both men and women), and the uniformity and detail with which comprehensive phenotypic assessments were conducted in CHARTER, a cohort designed specifically to study neurological outcomes of HIV infection. Genetic ancestry, a critical covariate in any genetic model of HAND, was also determined for all participants in CHARTER using identical methods to generate the PCs, and it was adjusted for accordingly in all models. Since all genetic data were available within one cohort and were obtained using a single (Affymetrix) platform, no imputation of SNP genotypes was conducted, and multiple (albeit related) measures of NCI of varying severity were used as outcomes for analysis, facilitating evaluation of robustness of any observed SNP associations across these phenotypes. This has not been possible in the field until now. However, this study did not include genome-wide analysis of longitudinal data or individual neurocognitive domains as in the study by Levine et al.; these analyses are ongoing. Results of ongoing longitudinal genome-wide analyses of neurocognitive decline will be reported in future. Results of imputation analyses, which have the advantage of revealing genotype calls for millions of additional SNPs beyond those included on the current platform, will also be reported in future work. Finally, this GWAS was conducted in a population that included women, and may be more representative of the modern ART era, since the distribution of HAND phenotypes more closely resembles the epidemiology of HAND in the ART era, with only a small minority of individuals carrying the diagnosis of HAD.
As has been noted previously, HAND is a challenging clinical phenotype, akin to other neuropsychiatric disorders, and its investigation is complex, due in part to fluctuations in the results of neurocognitive assessments within individuals over time [Kallianpur and Levine, 2014] . This study, performed using cross-sectional neurocognitive outcomes data obtained at baseline in CHARTER participants, is therefore, subject to random misclassification of individuals as impaired or unimpaired, which would be expected to bias our results toward the null [Hennekens and Buring, 1987] . As others have noted, detection of additive SNP associations with 80% power using an alpha (Type I error) level of 5 Â 10 À8 requires that the SNP account for at least 3.5% of the variability in the phenotype [Levine et al., 2012] . Despite being relatively common, the genetic variants we evaluated might not account for a sufficient proportion of the variability in the HAND phenotype for detection with 80% power in our study population, which also comprised several different ancestral subgroups. In addition to phenotypic complexity and population heterogeneity, the modest size of our sample, while not small, is still likely the major reason why more significant associations were not detected. Finally, since etiologic factors in HAND are varied, with involvement of immune/inflammatory, lifestyle, and concomitant comorbid and aging-related conditions, residual confounding of genetic effects by these other factors remains a consideration [Clifford and Ances, 2013] . However, the associations between neurocognitive outcomes and covariates other than age that have been linked to these outcomes in prior CHARTER studies and other HIV cohorts are reassuring in this regard. Due to the important need for replication, we have initiated collaborations with other large HIV cohorts with neurocognitive assessment data, to in order to significantly augment the sample size for genetic studies (N approximately 7000). The planned replication attempts will require genomic as well as outcome data harmonization beforehand, since neurocognitive assessment methods and genotyping platforms differed across studies.
In conclusion, this GWAS conducted among CHARTER study participants identified several new genes with possible roles in HAND, some of which approach genome-wide levels of significance. This study did not replicate SNPs previously observed to be associated with HAND, with the exception of a nominal association for MCP1. These new associations with HAND, although biologically plausible, remain to be replicated in larger studies of HIV-infected persons with longitudinal NC assessments. 
